Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTK NASDAQ:KRYS NASDAQ:NUVL NASDAQ:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$75.73-1.8%$64.00$29.31▼$80.20$9.40B0.382.07 million shs3.14 million shsKRYSKrystal Biotech$287.98+1.2%$262.18$122.80▼$303.00$8.47B0.5292,020 shs170,522 shsNUVLNuvalent$103.41+1.9%$101.96$63.56▼$113.01$8.13B1.15562,157 shs183,905 shsZYMEZymeworks$27.53+3.2%$25.47$10.86▼$29.75$2.03B1.2704,179 shs276,252 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics+21.69%+27.02%+15.53%+21.36%+110.23%KRYSKrystal Biotech+6.97%+5.68%+9.05%+5.74%+75.35%NUVLNuvalent+2.45%-0.46%-3.76%-3.35%+34.52%ZYMEZymeworks+0.26%-4.51%+3.41%+15.45%+2,667,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$75.73-1.8%$64.00$29.31▼$80.20$9.40B0.382.07 million shs3.14 million shsKRYSKrystal Biotech$287.98+1.2%$262.18$122.80▼$303.00$8.47B0.5292,020 shs170,522 shsNUVLNuvalent$103.41+1.9%$101.96$63.56▼$113.01$8.13B1.15562,157 shs183,905 shsZYMEZymeworks$27.53+3.2%$25.47$10.86▼$29.75$2.03B1.2704,179 shs276,252 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics+21.69%+27.02%+15.53%+21.36%+110.23%KRYSKrystal Biotech+6.97%+5.68%+9.05%+5.74%+75.35%NUVLNuvalent+2.45%-0.46%-3.76%-3.35%+34.52%ZYMEZymeworks+0.26%-4.51%+3.41%+15.45%+2,667,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTKCytokinetics 2.82Moderate Buy$96.7527.76% UpsideKRYSKrystal Biotech 2.83Moderate Buy$324.1112.54% UpsideNUVLNuvalent 2.88Moderate Buy$137.2532.73% UpsideZYMEZymeworks 2.92Moderate Buy$37.8937.63% UpsideCurrent Analyst Ratings BreakdownLatest ZYME, CYTK, NUVL, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026CYTKCytokinetics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$90.00 ➝ $103.005/6/2026CYTKCytokinetics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$119.005/6/2026CYTKCytokinetics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$101.00 ➝ $119.005/6/2026CYTKCytokinetics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$108.005/5/2026CYTKCytokinetics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$106.005/5/2026KRYSKrystal Biotech EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$300.005/5/2026KRYSKrystal Biotech CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$371.00 ➝ $378.005/5/2026CYTKCytokinetics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$85.00 ➝ $102.005/4/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.004/27/2026ZYMEZymeworks Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026NUVLNuvalent Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTKCytokinetics$88.04M106.86N/AN/A($5.39) per share-14.05KRYSKrystal Biotech$389.13M21.79$7.32 per share39.36$43.37 per share6.64NUVLNuvalentN/AN/AN/AN/A$15.95 per shareN/AZYMEZymeworks$105.96M19.16N/AN/A$3.59 per share7.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTKCytokinetics-$784.96M-$6.53N/AN/AN/A-891.60%N/A-49.62%N/AKRYSKrystal Biotech$204.83M$6.8538.4526.20N/A53.92%19.25%17.62%N/ANUVLNuvalent-$425.38M-$5.85N/AN/AN/AN/A-39.29%-35.01%5/7/2026 (Estimated)ZYMEZymeworks-$81.13M-$1.08N/A39.90N/A-76.56%-26.00%-20.57%5/7/2026 (Estimated)Latest ZYME, CYTK, NUVL, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026NUVLNuvalent-$1.35N/AN/AN/A$0.49 millionN/A5/7/2026Q1 2026ZYMEZymeworks-$0.10N/AN/AN/A$24.38 millionN/A5/5/2026Q1 2026CYTKCytokinetics-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 million3/2/2026Q4 2025ZYMEZymeworks-$0.35-$0.55-$0.20-$0.55$21.78 million$2.52 million2/24/2026Q4 2025CYTKCytokinetics-$1.48-$1.50-$0.02-$1.50$8.02 million$17.76 million2/17/2026Q4 2025KRYSKrystal Biotech$1.62$1.70+$0.08$1.70$105.30 million$107.11 million2/14/2026Q4 2025ZYMEZymeworksN/A-$0.55N/A-$0.55N/A$2.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCYTKCytokineticsN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTKCytokineticsN/A4.534.53KRYSKrystal BiotechN/A9.959.56NUVLNuvalentN/A15.2715.27ZYMEZymeworksN/A5.885.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTKCytokineticsN/AKRYSKrystal Biotech86.29%NUVLNuvalent97.26%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipCYTKCytokinetics2.60%KRYSKrystal Biotech13.10%NUVLNuvalent10.20%ZYMEZymeworks33.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTKCytokinetics250124.24 million121.01 millionOptionableKRYSKrystal Biotech21029.44 million25.58 millionOptionableNUVLNuvalent4078.62 million70.60 millionOptionableZYMEZymeworks46073.75 million49.04 millionN/AZYME, CYTK, NUVL, and KRYS HeadlinesRecent News About These CompaniesPictet Asset Management Holding SA Invests $1.97 Million in Zymeworks Inc. $ZYMEMay 5 at 4:58 AM | marketbeat.comKornitzer Capital Management Inc. KS Takes $2.34 Million Position in Zymeworks Inc. $ZYMEMay 3 at 7:02 AM | marketbeat.comBMS calls time on Zymeworks collab, ending work on phase 1 cancer bispecificApril 30, 2026 | fiercebiotech.comFZymeworks (ZYME) Projected to Post Earnings on ThursdayApril 30, 2026 | marketbeat.comZymeworks (NASDAQ:ZYME) Raised to Strong-Buy at Truist FinancialApril 28, 2026 | marketbeat.comZymeworks (NASDAQ:ZYME) Hits New 52-Week High - Time to Buy?April 28, 2026 | marketbeat.comZymeworks Highlights Royalty-Fueled Pivot at Bloom Burton, Eyes Multibillion-Dollar ZiiheraApril 26, 2026 | marketbeat.comZymeworks Inc. (NASDAQ:ZYME) Receives Consensus Rating of "Moderate Buy" from AnalystsApril 23, 2026 | marketbeat.comZymeworks (NASDAQ:ZYME) Hits New 1-Year High - What's Next?April 22, 2026 | marketbeat.comZymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026April 21, 2026 | globenewswire.comAACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new dataApril 21, 2026 | biospace.comBZymeworks Inc.: Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting PlatformApril 17, 2026 | finanznachrichten.deZymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting PlatformApril 17, 2026 | globenewswire.comHow Investors May Respond To Zymeworks (ZYME) Hiring EcoR1 Executives To Lead R&D And DealsApril 17, 2026 | finance.yahoo.comZymeworks Sets May 7 Date to Unveil Q1 2026 Results and Pipeline UpdateApril 16, 2026 | tipranks.comZymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026April 16, 2026 | financialpost.comFZymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026April 16, 2026 | globenewswire.comJPMorgan Chase & Co. Cuts Stock Position in Zymeworks Inc. $ZYMEApril 13, 2026 | marketbeat.comZymeworks announces leadership appointmentsApril 9, 2026 | thepharmaletter.comTZymeworks Announces Additional Leadership Appointments to Advance Next Phase of GrowthApril 9, 2026 | financialpost.comFZymeworks Announces Additional Leadership Appointments to Advance Next Phase of GrowthApril 9, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZYME, CYTK, NUVL, and KRYS Company DescriptionsCytokinetics NASDAQ:CYTK$75.83 -1.26 (-1.63%) As of 03:33 PM Eastern This is a fair market value price provided by Massive. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Krystal Biotech NASDAQ:KRYS$287.26 +2.70 (+0.95%) As of 03:32 PM Eastern This is a fair market value price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Nuvalent NASDAQ:NUVL$103.51 +2.04 (+2.01%) As of 03:33 PM Eastern This is a fair market value price provided by Massive. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Zymeworks NASDAQ:ZYME$27.55 +0.87 (+3.26%) As of 03:32 PM Eastern This is a fair market value price provided by Massive. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage Years in the Making, AMD’s Upside Movement Has Just Begun Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Pinterest Pins a Profit Play To Its Mood Board Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
